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INCREASING HUMAN PAPILLOMAVIRUS VACCINATION AMONG 
ADOLESCENTS THROUGH PARENT TARGETED CANCER-PREVENTION 
EDUCATION 
 
 
An Abstract of the Scholarly Project by 
Shannon Leigh Duncan 
 
 
The purpose of this study was to determine if parent targeted HPV education 
emphasizing the cancer-prevention benefits of vaccination increased initiation of the 
Gardasil 9 series among adolescents attending Pittsburg Community Middle School 
(PCMS).  This project was completed in conjunction with the Southeast Kansas 
Community Health Center (SEK CHC) and consisted of providing HPV and Gardasil 9 
education to the parents/legal guardians of the students enrolled at PCMS one week prior 
and during the 2018 parent-teacher conference sessions.  An informational mailer was 
sent out to all parents/legal guardians of the PCMS students and live one-on-one 
educational encounters were provided to those who attended one of the conference 
sessions.  An opt-out survey was issued to willing parent/legal guardian participants to 
aid in determining barriers against HPV vaccination.  Data was collected from the SEK 
CHC KidCare school health van’s electronic medical records to compare initiation of the 
Gardasil 9 series from October 25th-November 29th, 2017, when no education was 
provided, versus October 25th-November 29th, 2018, six weeks after the parent-teacher 
conference educational intervention.  An increase in Gardasil 9 initiation was noted in the 
six weeks post-education in 2018 when compared to the same time frame in 2017.  The 
results of this study indicate HPV education focusing on cancer prevention have a 
positive effect on obtaining parent/legal guardian consent for HPV vaccination. 
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Chapter I 
 
 
Introduction 
 
 
Human Papillomavirus, often referred to as HPV, is a sexually transmitted 
infection (STI) that affects approximately 76 million people in the United States, making 
it the most common STI in America (Farmar et al., 2016).  Of the millions infected with 
this virus, it is estimated that 33,000 of these cases will result in either cervical, vulvar, 
anal, oropharyngeal, or penile cancers per year (Farmar et al., 2016).  The incidence for 
HPV related-cancers is as follows: 96%-99% of cervical cancers, 90%-93% of anal 
cancers, 12%-63% of oropharyngeal cancers, 36%-40% of penile cancers, 40% of vaginal 
cancers, and 40%-51% of vulvar cancers (Thomas, 2016).  The annual cost of managing 
HPV infection and the cancers that result in both males and females is $252 million 
(Thomas, 2016). 
Description of the Problem 
 Human Papillomavirus is a self-initiating virus that attacks when it encounters a 
cellular surface and within 24 hours of contact has incorporated its own DNA into the 
basal cells’ nuclear DNA (Thomas, 2016).  Once the viral genetic material has undergone 
cellular replication, proteins are produced that further advance the infection (Thomas, 
2016).  These proteins allow the HPV viral cells to form two different layers that promote 
binding to basal cells in areas such as the base of the tongue, oropharynx, and cervix 
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(Thomas, 2016).  The probability these cellular changes will result in precancerous and 
cancerous lesions is related to the persistence and type of infection (Castle & Maza, 
2015).  In adolescent and young women, there are areas of the cervix that undergo rapid 
cellular changes, making them a host to HPV cells (Ratanasiripong, 2014).  Exposure to 
HPV during this time frame, especially for females, significantly increases the risk of 
HPV infection (Ratanasiripong, 2014).  Vulnerability to HPV is greater when vaccination 
occurs after potential exposure (Castle & Maza, 2015).  If the Gardasil 9 series is 
provided at a younger age, there is a higher probability repeated encounters with various 
HPV strains should not result in cellular mutations that lead to the formation of cancerous 
lesions.  There are multiple strains of HPV but 70% of the cancers that result from this 
infection are caused by two types, HPV-16 and HPV-18 (Castle & Maza, 2015).    
 In 2006, the Food and Drug Administration (FDA) approved the use of Gardasil, 
a prophylactic quadrivalent vaccination protecting against HPV strains 6, 11, 16, and 18 
(Castle & Maza, 2015).  In 2007, the Centers for Disease Control (CDC) and Advisory 
Committee for Immunization Practices (ACIP) recommended the routine use of a 3-shot 
series with quadrivalent Gardasil as the primary prevention of HPV infection in women 
9-26 years old (Castle & Maza).  Two years later, in 2009, the CDC and ACIP amended 
its previous recommendation to include males between 11 to 26 years old (Thomas, 
2016).   In February 2015, Gardasil 9 (a 9-valent vaccine protecting against strains 6, 11, 
16, 18, 31, 33, 45, 52, & 58) became FDA approved with a 97% efficacy rate in 
protecting against infections and resultant HPV-related cancers, replacing the 
quadrivalent Gardasil (Thomas, 2016).  Current CDC and ACIP guidelines recommend 
Gardasil 9 vaccination for males 9 to 15 and females 9 to 26 (Thomas, 2016). Because 
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HPV is sexually transmitted, the 20 to 24 year old age group is at the highest risk for 
exposure and infection (Ratanasiripong, 2014).  Therefore, those receiving the greatest 
benefit from Gardasil 9 are the individuals that have yet to be exposed, specifically 
adolescents between 11 and 14 years old (Castle & Maza, 2015). 
Unfortunately, despite the insistence by the CDC and ACIP to vaccinate, less than 21% 
of males and 60% of females in the United States have received the recommended 
vaccination series (Thomas, 2016).  This lack of uptake has led to 79 million people 
currently infected and 14 million newly diagnosed cases each year (Farmar et al., 2016).   
 Although the statistics mentioned above refer to the age span eligible for the 
vaccine, the numbers specifically reflecting young adolescents (11 to 14) are just as 
unsettling, especially in the state of Kansas.  According to the CDC, only 50-59% of 11 
to 14 year-old Kansas residents have received one or more of the Gardasil 9 series, and 
the vaccination rate for HPV in Crawford County is staggeringly less at 10% (CDC, 
2017). 
Parents of early adolescents are often naïve to their child’s eventual sexual activity and 
therefore, their exposure to STIs, such as HPV (VanWormer, et. al, 2017).  It is important 
providers emphasize education about HPV vaccination to parents focusing on its efficacy 
and safety to prevent prevalent cancers and not solely on current or eventual sexual 
behaviors.  Even though HPV is a sexually transmitted infection, the vaccination does not 
contribute to the act of sexual intercourse in any way (Ratanasiripong, 2014).  It simply 
prevents infection from further advancing into precancerous, cancerous, or malignant 
disease. 
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Significance to Nursing 
 Practitioner guidance when it comes to vaccine guidelines and schedules is an 
important source of education for parents.  During adolescence, important recommended 
vaccines include Hepatitis A, Hepatitis B, meningococcal, and tetanus, diphtheria, and 
acelluar pertussis (Tdap), and several of these are offered through the public-school 
system (Castle & Maza, 2015).  There is no contraindication to administration of the 
HPV vaccine with the other vaccinations recommended for this age group (Castle & 
Maza, 2015).  Therefore, there is no reason primary care providers (PCPs) shouldn’t 
strongly recommend HPV vaccination be included in this series. 
 In rural communities like Crawford County, parents’ knowledge of HPV and its link to 
cancer is very minimal (Thomas, 2016).  When primary care providers are appropriately 
educated on Gardasil 9 and its recommended use, the education gap present in the parent 
population can be bridged.  However, lack of education is not the only barrier to 
increasing rural vaccination rates.  Additionally, the perception of HPV and its relation to 
sexual activity and/or behaviors may have a negative effect on vaccination consent.  The 
cancer-causing abilities of HPV need to be the primary focus of parent education, not the 
method of transmission.  An increase in education of HPV-related cancers is a 
responsibility of providers if attitudes toward the Gardasil series are going to change.   
Purpose 
 The aim of this scholarly project is to improve HPV vaccination uptake among 
the Pittsburg Community Middle School (PCMS) student body.  The overall goal of this 
project is to implement an educational intervention designed to increase parental consent 
for HPV vaccination.  The purpose of this evidence-based research project is to 1) 
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increase HPV vaccination uptake in 11 to 14 year old adolescents in the student body of 
PCMS; 2) provide parent education on HPV vaccination that focuses on cancer 
prevention; 3) change perception of Gardasil 9 from prevention of a STI to cancer 
prevention.  It is crucial to break the association of vaccinating against HPV to sexual 
activity and redirect the focus toward prevention of an aggressive cancer-causing virus.   
Conceptual Framework 
 The conceptual framework chosen for this project is the Vaccine Perceptions, 
Accountability, and Adherence Model.  This model was developed by Dr. Ingrid T. Kratz 
of Brigham and Women’s Hospital, Dr. Norma C. Ware of Harvard Medical School, Dr. 
Glenda Gray of the Univeristy of Witwatersrand, Dr. Jessica E. Haberer of Harvard 
Medical School, Dr. Claude A. Mellins of New York State Psychiatric Unit and 
Columbia University, and Dr. David R. Bangsberg of Harvard Medical School in 2010 as 
a means to better understand HPV vaccine adherence, completion, and efficacy among 
adolescents (Katz, et al., 2010).  The developers of this model took into account various 
factors affecting vaccine acceptance and the potential barriers that contribute to 
completion of the series among both adolescents and parents/caregivers (Katz, et al, 
2010).   
 The following diagram (Figure 1) shows The Vaccine Perceptions, 
Accountability, and Adherence Model.  It depicts multiple sociocultural factors at various 
stages of the vaccination series that often act as barriers for vaccine denial or neglect of 
completion (Katz, et al., 2010).  The application of this model is intended to assist 
research targeted to better understand the obstacles that stand in the way of HPV vaccine 
education, uptake, and adherence (Katz, et al., 2010).    
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Fig. 1 The vaccine perceptions, accountability, and adherence model.  Adapted from 
“Scaling Up Human Papillomavirus Vaccination: A Conceptual Framework of Vaccine 
Adherence” by Katz, I.T., Ware, N.C., Gray, G., Haberer, J.E., Mellins, C.A., & 
Bangsberg, D. R., 2010, Sexual Health, 7(3), 279-286. 
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Research Questions 
1. What are the perceived barriers to HPV vaccination of adolescent 
parents/legal guardians in a rural southeast Kansas school district who opt-out 
of HPV vaccination for their child and attended parent-teacher conferences? 
2. Will education focusing on cancer prevention increase parental consent to 
vaccinate against HPV in 11 to 14 year olds among the parents/legal guardians 
that received the mailer and those who received the mailer, as well as attended 
parent-teacher conferences in 2018? 
3. Will the Southeast Kansas Community Health Center KidCare school health 
van see an increase in vaccination among 11 to 14 year olds six weeks post 
education in children whose parents/legal guardians received the mailer and 
those that received the mailer and one-on-one education at parent-teacher 
conferences vs the 2017 fall semester when no education was provided? 
Definition of Key Terms 
 The following terms will be seen frequently by the reader throughout this paper.  
For better understanding, the definitions are provided here.  The terms and definitions 
include: adolescents, cancer, Center for Disease Control (CDC), Gardasil 9, human 
papillomavirus, Pittsburg Community Middle School, primary care provider, sexually 
transmitted infection, Southeast Kansas Community Health Center, uptake, vaccine. 
 Adolescent- growing into manhood or womanhood (Adolescent, 2018) 
 Cancer- a term for diseases in which abnormal cell growth occurs and can invade 
nearby tissues or spread to other parts of the body (NCI Dictionary of Cancer Terms, 
2018)  
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Center for Disease Control (CDC)- major operating component of the 
Department of Health and Human Resources that works to protect America from health, 
safety, and security threats, both foreign and in the U.S. (CDC Organization, 2018) 
 Gardasil 9- a vaccine used to prevent anal, cervical, vulvar, vaginal, penile, and 
oropharyngeal cancers caused by nine different strains of human papilloma virus (NCI 
Dictionary of Cancer Terms, 2018) 
 Human papillomavirus- a sexually transmitted type of virus that can cause 
abnormal tissue growth and other changes to cells that, over time, can develop into cancer 
(NCI Dictionary of Cancer Terms, 2018) 
 Pittsburg Community Middle School (PCMS)- Public school in the USD 250 
school district in Pittsburg, KS for grades 6, 7, & 8 
 Primary care provider- individual that assess, manages, and treats individuals 
with acute and chronic medical conditions; physicians, physician’s assistant, or nurse 
practitioner (Primary Care Provider, 2018) 
 Sexually transmitted infection- bacteria, viruses, or parasites known to be 
transmitted through sexual contact whether it be vaginal, anal, or oral (Sexual and 
reproductive health, 2018) 
 Southeast Kansas Community Health Center- a Federally Qualified Health 
Center dedicated to providing quality health care to everyone regardless of income or 
insurance status with twelve clinic sites in Crawford, Cherokee, Labette, Montgomery 
and Allen counties (Community Health Center of Southeast Kansas, 2018). 
 Uptake- an act or instance of taking up or adopting (Uptake, 2018) 
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 Vaccine- a biological preparation that improves immunity to a particular disease 
(Vaccines and Immunizations, 2018) 
Logic Model 
 The following diagram (Figure 2) is a logic model that depicts the identification 
of HPV vaccination barriers, development of educational resource to overcome barriers, 
and expected outcomes of increased HPV education.  The Southeast Kansas Community 
Health Center and its traveling school nurse van, USD 250 superintendent, Pittsburg 
Community Middle School administrative staff and school act as key stakeholders in the 
input stage of this project.  Assessment of HPV vaccination uptake and adherence among 
these stakeholders provide needed information to organize and develop an educational 
resource that correlates HPV vaccination with cancer prevention.  Participation and 
implementation by the SEK Community Health Center and their school nurse mobile 
clinic (KidCare van) will, ideally, lead to the outcomes depicted. 
 The outcomes portion of this model have been divided into three time frames, 
short, medium (intermediate), and long term outcomes.  The most immediate responses 
predicted from the educational intervention include a change in perception of HPV 
vaccination and an increase in 11 to 14 year olds vaccinated.  With continuation of 
education focused on cancer prevention, it is anticipated attitudes toward the Gardasil-9 
series will shift away from the fact that HPV is sexually transmitted.  In addition, it is the 
hope of the researcher that with increased awareness parents will begin to initiate 
discussion of HPV vaccination and adolescents will become vaccinated prior to HPV 
exposure.  The ultimate long-term outcomes will be to reach the Healthy People 2020 
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goal of 80% vaccination rate and an overall reduction in the incidence of HPV-related 
cancers in Crawford County. 
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Fig. 2  HPV Vaccine Adherence Logic Model  
 12 
Summary 
 Even though vaccination is one of the most common health-promoting behaviors 
patients and practitioners participate in, HPV vaccination has yet to be considered a 
routine vaccine in the way that Hepatitis B and Meningococcal vaccines are (Thomas, 
2016).  The question remains: for what reasons are HPV vaccination rates still so low 
nationally, statewide, and locally?  There is abundant knowledge on how and why HPV 
vaccination works to prevent multiple cancers in men and women.  However, to get the 
maximum vaccination effect against HPV, it is necessary to undergo the Gardasil 9 series 
before potential exposure to the virus occurs.  The vaccine’s cancer-preventing benefits 
are greatest at this time, so increasing HPV vaccination rates among young adolescents 
may eventually decrease the incidence of HPV-related cancers.  In an effort to increase 
vaccination rates, the HPV vaccine needs to be associated with cancer prevention and not 
sexual activity or behaviors by providers, patients, and their parents/legal guardians. 
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Chapter II 
 
 
Literature Review 
 
 
The attempt to determine a reason behind the low uptake of the Human Papillomavirus 
(HPV) vaccine, specifically in the rural setting, requires a review of literature to examine 
similarities, differences, and patterns of behaviors among providers and adolescent 
patients and their parents.  This literature review was conducted using the online 
databases CINAHL and PubMed.  All articles were obtained from peer-reviewed journals 
using the keywords: Human Papillomavirus, HPV, vaccination rates, Gardasil, safety, 
rural, and vaccine uptake.  A significant amount of research has been conducted on HPV 
vaccination rates and the reasoning behind low uptake.  Using the keywords above, 26 
articles met the criteria for review.  The criteria required for the articles selected for 
review were as follows: published in the last five years, primary study, adolescent and 
young adult study population, and provider/patient barrier analysis.  The CDC website 
was utilized to determine current statistics regarding HPV vaccination rates nationally 
and locally.  The ACIP Guidelines were also reviewed in relation to the recommended 
practices of HPV vaccine administration.  This review highlights some of the barriers 
identified and intervention proposed and implemented to overcome low vaccine uptake. 
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Rural Vaccination Rates 
 Rural vaccination rates for patients of all ages has been extensively studied.  Data 
was collected from both adolescents’ parents and young adult/college-age individuals 
eligible to receive HPV vaccination to attempt to determine the reasoning behind poor 
vaccine uptake in rural communities (Lai, Ding, Bodson, Warner, & Kepka, 2016; 
Crosby, Casey, Vanderpool, Collins, & Moore, 2011).  Results established parents older 
than 45-years-old were less likely to consent to vaccination when compared with parents 
35 and younger (Lai et al., 2016).  The parents of 17 year old study participants were also 
more likely to initiate and complete the series than those of the 13 year olds (Lai et al., 
2016).  Vaccine compliance during infancy and childhood was associated with greater 
compliance (Lai et al., 2016).  Study participants that were up-to-date with immunization 
had higher prevalence of HPV vaccine initiation and completion (Lai et al., 2016).  
 Another possible barrier to vaccination is the personal cost of vaccination.  In a 
rural Kentucky study, college-aged women (18 to 26) and were given a Women’s Health 
Questionnaire followed by a voucher to receive Gardasil 9 for free, therefore eliminating 
any cost component restrictions (Crosby et al., 2011).  Despite the offer of free 
vaccination, rural women were seven times less likely to complete the vaccine series than 
their urban counterparts eliminating financial hardship as a barrier (Crosby et al., 2011).  
Therefore, it is difficult to determine which variables are most responsible for lack of 
vaccine follow-through by rural adolescent parents and young adult women. 
Parental Barriers 
 Ultimately, parent consent is needed before HPV vaccination can be administered, 
especially in the target age group of 11 to 14, but how to obtain consent remains a very 
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important and unanswered question.  Between 2009-2014, 52.1 % of adolescents (mean 
age of 11.2 years) received tetanus-diptheria-acellular pertussis (Tdap), 45.8% received 
from meningococcal (MenACWY), and only 18.4% were vaccinated for HPV (Vielot, 
Butler, Brookhart, Becker-Dreps, & Smith, 2017).  Several of the studies selected for this 
review identified parental lack of HPV knowledge and lack of provider recommendation 
as the two main barriers in vaccinating for HPV (Vielot et al., 2017; Brown, Gobra, & 
Pellman, 2017; VanWormer, et al., 2017; Cates, Shafer, Diehl, & Deal, 2011).  A 
California pediatric clinic began surveying parents in January 2015 to determine their 
reasoning behind agreeing or refusing to vaccinate for HPV (Brown, Gobra, & Pellman, 
2017).  Researchers found strength of provider recommendation to be the most common 
reason for consenting to vaccinate (84.1%) and information availability as the second 
most common reason accounting for 63.4% of parents surveyed (Brown, Gobra, & 
Pellman, 2017).  Similar results were found in a survey-based study done at a Wisconsin 
clinic, where parents’ preconceived attitudes toward HPV were assessed and education 
was tailored to address primary concerns, which mostly consisted of vaccine 
effectiveness and safety (VanWormer, et al., 2017).  This resulted in 60% of adolescent 
patients receiving a second dose and 38% completing the three-shot series (VanWormer, 
et al., 2017). 
 Social marketing has also been shown to assist in increasing HPV vaccination 
rates.  In North Carolina, a social marketing campaign was deployed in four medically 
underserved, rural counties from June 2009-November 2009 (Cates, Shafer, Diehl, & 
Deal, 2011).  The campaign included placing educational materials and reference 
information focusing on the HPV vaccine’s cancer-preventing benefits, in physicians’ 
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offices and settings where mothers of the target age group (9 to 13) frequented (Cates, 
Shafer, Diehl, & Deal, 2011).  Data analysis revealed a 2% increase in HPV vaccination 
rates in the selected counties versus non-intervention counties (Cates, Shafer, Diehl, & 
Deal, 2011).  Although this isn’t a vast improvement, the social marketing campaign 
solidifies the hypotheses that increased education and availability of resources has a 
positive effect on improving HPV vaccination rates. 
Misconceptions on Sexual Behavior 
Lack of knowledge regarding HPV vaccination has led to parental misconception 
on the after-effects of vaccine administration (Ratanasiripong,2014).  One of the main 
misconceptions about the vaccine is that it has an effect on post-vaccine sexual behaviors 
(Ratanasiripong, 2014).  Multiple factors have been used to define “sexual behavior”.  
The defining characteristics for measuring vaccination effects on sexual behavior consist 
of age at initiation of intercourse, number of sexual partners, and consistent use of 
condoms and other safe sex practices (Ratanasiripong, 2014). 
The correlation of vaccination for HPV and sexual behavior in both the young adult and 
young female population is complex. Sexual behaviors in the age group in which initial 
vaccination is recommended has not been thoroughly studied but has been evaluated 
among the older adolescent and young adult age groups (Mullins, Widdice, Rosenthal, 
Zimet, & Kahn, 2015).  Since exposure increases with age, young adolescents are 
expected to have the greatest benefit from the HPV vaccine because, in most cases, they 
have yet to be exposed to the virus (Castle & Maza, 2015).  In a 2015 study, sexual 
attitudes and perceptions were evaluated among 11 to 12 year old girls, their mothers and 
clinicians.  Even though multiple sources of data were included in this study, findings 
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indicated that HPV vaccination was unlikely to affect girls’ sexual behavior and attitudes 
(Mullins, Widdice, Rosenthal, Zimet, & Kahn, 2015).  As knowledge about HPV, the 
cancerous effects of the virus, and the vaccine increased, risk sensitivity of HPV became 
more accurate, with several subjects reporting that HPV and vaccine knowledge 
correlated with safer sexual attitudes (Mullins, Widdice, Rosenthal, Zimet, & Kahn, 
2015).  It is also worth noting the participants with the greatest knowledge of HPV prior 
to the vaccination remained sexually inactive throughout the 30 month study (Mullins, 
Widdice, Rosenthal, Zimet, & Kahn, 2015).  Hansen, et al. (2014) performed a 
retrospective cross-sectional survey of approximately 44,000 women, 3,805 having 
received vaccination against HPV.  The survey results showed HPV vaccination was not 
associated with initiation of sexual intercourse at a younger age (Hansen, et al., 2014).  
Additionally, data showed the number of sexual partners was not significantly higher in 
vaccinated women vs. unvaccinated women and contraception use was more consistent 
among the vaccinated participants (Hansen, et al., 2014).  Population size varied from 
less than one hundred to just over 100,000 across the studies.  Essentially, all of the 
studies reviewed drew the same conclusion that HPV vaccination did not promote or 
enhance sexual promiscuity.  However, because of the varying population sizes, multiple 
age groups, and convenience sampling in selection of the participants, there is still a lack 
of generalizability among the results. 
Safety & Efficacy 
 Informed consent is necessary to obtain parental permission to vaccinate against 
HPV, therefore providers must be well versed in discussing the safety and efficacy of 
vaccinating with Gardasil 9.  As with any vaccine administered to children, parental 
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concerns of adverse health effects that may result from vaccination effects uptake impact 
(Zimet, Rosbeger, Fisher, Perez & Stupiansky, 2013).  Adverse effects associated with 
Gardasil 9 have been thoroughly studied to determine if the benefits of vaccination 
outweigh the risks.   
The most commonly described injection-site adverse effects from receiving either one or 
both shots in the Gardasil 9 series are: pain at injection site, swelling, erythema, pruritus 
and hematoma (Garland, et al., 2015; Zimet, Rosberger, Fisher, Perez, & Stupiansky, 
2013).  In a study population of 618 subjects, mild to moderate injection-site symptoms 
were the most frequently reported adverse reaction (Garland, et al., 2015).  Out of that 
same study population, 7.6% experienced severe injection-site swelling and 3.3% 
experienced severe injection-site swelling and erythema (Garland, et al., 2015).  Only one 
test subject had a severe enough injection-site reaction with the first shot in the series that 
they did not receive the second shot (Garland, et al., 2015).  Vaccine-related systemic 
adverse effects were also evaluated in this study.  Systemic reactions reported were 
headache, pyrexia, nausea, and dizziness with a less than 2% incidence among 
participants (Garland, et al., 2015).  Only one test subject in the 2015 study experienced a 
severe systemic response with the initial Gardasil 9 shot (Garland, et al., 2015).  This 
subject was diagnosed with tonsillitis that required surgical incision and drainage of the 
tonsils (Garland, et al., 2015).  The patient was treated with antibiotics and fully 
recovered with no further residual effects (Garland, et al., 2015).  No fatalities as a result 
of HPV vaccination occurred in any of the studies included in this literature review 
(Garland, et al., 2015; Petersen, et al., 2017; Schilling, et al., 2015; & Zimet, Rosberger, 
Fisher, Perez, & Stupiansky, 2013).  Additionally, reported adverse effects occurring 
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after vaccination does not necessarily mean they were a result from the vaccine (Zimet, 
Rosberger, Fisher, Perez, & Stupiansky, 2013). 
In addition to studying the safety of the Gardasil 9 vaccine, its efficacy has been 
thoroughly evaluated as well.  The Gardasil vaccine is 9-valent, meaning it protects 
against 9 different categories of the HPV virus (6, 11, 16, 18, 31, 33, 45, 52, 58) 
(Petersen et al., 2017).  Administration of the series initiates a powerful immune system 
response to all 9 strains in study participants of all ages, races, and geographic 
backgrounds (Petersen et al., 2017).  Blood testing for immunization effectiveness has 
been performed on a variety of age groups of both genders with results suggesting that 
stronger immunity to all 9 HPV strains occurs in young adolescents who have not yet 
been exposed to HPV (Petersen et al., 2017).  Because the optimal age for HPV 
vaccination is the same age the Tdap booster and meningococcal vaccine are required, 
Gardasil 9 efficacy with co-administration of these vaccines has also been evaluated.  
Schilling, et al. (2015) showed the immune response when all 3 vaccines were 
administered together was just as adequate as when they were given one month apart.  
The ability to administer all 3 vaccines at the same visit is beneficial in creating greater 
vaccine compliance (Schilling, et al., 2015). 
Cancer Screening Impact 
 Although not enough time has elapsed since Gardasil 9’s introduction to 
determine an accurate effect on the incidence of cervical cancer, studies have been 
performed world-wide on how HPV vaccination has impacted cervical cancer screening 
and the rate of cervical lesion detection.  In countries such as Australia, that have 
implemented a national and publically funded HPV vaccination program, the vaccinated 
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female population is more likely to be compliant with cervical cancer screening 
guidelines (Canfell, et al., 2017).  A study completed in the UK showed an increase in 
routine cervical cancer screening among the mothers who consented for vaccination of 
their adolescent daughters  (Spencer et al., 2015).  Munro et al. (2017) looked at the 
incidence of HPV strains found on colposcopy in a group of women that were offered the 
vaccine through a “catch-up” vaccine program.  The sample population consisted of 361 
women aged 20 to 25 years who had been referred for colposcopy due to abnormal 
cytology results (Munro, et al., 2017).  The HPV 16 strain was found on colposcopy 
specimen in 8.6% of the vaccinated group and 46.7% of the unvaccinated group, showing 
the effectiveness of HPV vaccination (Munro, et al., 2017).  A similar study done in 
Denmark researched the incidence of cervical lesions in women who had received the 
vaccine during adolescence (Baldur-Felskov, Dehlendorff, Junge, Munk, & Kjaer, 2014).  
Using the female population prior to Denmark’s vaccination program (2000-2010) as a 
control group, researchers found the incidence of cervical lesions was increased among 
all age groups prior to 2010 (Baldur-Felskov, Dehlendorff, Junge, Munk, & Kjaer, 2014).  
The most statistically significant decrease in cervical lesions was seen in the population 
with high HPV vaccine uptake after the initiation of the vaccination program in 2010 
(Baldur-Felskov, Dehlendorff, Junge, Munk, & Kjaer, 2014). 
Provider Intervention 
 Parent and patient barriers are not the only factor to consider in the lack of HPV 
vaccine uptake.  Provider vaccination practices must also be considered in the research of 
low HPV vaccine uptake.  A user-centered design approach was conducted at the Kaiser 
Permanente Center in Portland, Oregon.  Researchers conducted interviews with six 
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primary care providers, five subject matter experts (two clinician performance 
consultants, a clinical program coordinator, a social marketing and health 
communications consultant, and a PhD-level researcher specializing in vaccine 
compliance research), and three industry representatives (a middle school guidance 
counselor, a marijuana legislation activist, and a retail curriculum expert) on knowledge, 
attitudes, and belief of HPV vaccination and potential perceived barriers to 
recommendation of the vaccine (Henninger, et al., 2017).  The data from the interviews 
was synthesized and a 4-hour workshop was attended by the interview participants as 
well as other stakeholders, such as parents of adolescents, with the intention of 
intervention development to be utilized in the clinic (Henninger, et al., 2017).  From this 
workshop, it was determined that interventions to be implemented to improve 
communication and administration of the HPV vaccine must focus on: enhancing trust, 
rapport, and communication, enhancing clinician knowledge of parental concerns, design 
of topic approach, and increasing clinicians’ comfort with discussing difficult topics 
(Henninger, et al., 2017).  Five potential interventions were proposed using the themes 
identified in the workshop to increase effectiveness of clinician communication with 
parents and adolescents about HPV vaccination (Henninger, et al., 2017).  Researchers 
concluded the user-centered design approach is an effective and efficient tool for 
developing interventions to improve HPV vaccination rates within the clinical setting 
(Henninger, et al., 2017).  However, none of these proposed interventions were 
implemented and studied for effectiveness.  In a different study, interventions focused on 
provider/staff education of HPV vaccination and clinic practices on vaccine reminder 
notifications (McLean, et al., 2017).  The study took place between February 2015 and 
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March 2016 and showed an increase in HPV vaccination from 41% to 59% among 
adolescents aged 11-12 years in the intervention clinics (McLean, et al., 2017).  In the 
control clinics, vaccination rates increased as well, but were less significant improving 
from 32% to only 45% (McLean, et al., 2017).  Results of this study show the impact of 
proper provider/staff education and patient reminder/recall on HPV vaccination rates.  
Summary 
The prevalence of HPV and the cancers that result from the infection pose a significant 
public health issue.  Reduction of the cost to manage and treat HPV-related STIs and the 
various cancers that may result from the virus is a public policy issue that should be 
considered by primary care providers as well.  Primary providers must be thoroughly 
educated so that accurate and appropriate information about the cancer preventing 
benefits of HPV vaccination are provided to the vaccine’s target populations so that those 
patients may make a correctly informed decision.   
 The articles referenced in this literature review provide a great deal of information 
from a variety of perspectives to enlighten health care providers the perceived barriers to 
consenting to HPV vaccination.  Populations and settings of the various studies reduces 
generalizability of the data but the similarities found in the results are a strong testament 
to their validity.  Barriers and interventions revealed throughout this review provide a 
solid foundation for this scholarly project. 
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Chapter III 
 
 
Methodology 
 
 
The project design and target population were selected after analysis of the CDC’s and 
ACIP’s recommendations of Human Papillomavirus (HPV) vaccination among 
adolescents, as well as a review of literature about the benefits of vaccinating this age 
group with Gardasil 9.  The target population for this study was chosen because the 11 to 
14 year old age group is believed to have the greatest long-term benefits from 
vaccination.  Human Papillomavirus exposure, especially repeated encounters, is proven 
to be associated with development of cervical, vaginal, vulvar, penile, anal, and 
oropharyngeal cancers.  The focus of this research is to provide education that correlates 
HPV vaccination with cancer prevention, therefore increasing the vaccination rate of 11 
to 14 year olds attending PCMS in Pittsburg, KS.  Immunizations are offered on-site by 
the SEK CHC traveling school health van (KidCare van).  This chapter will discuss the 
methodology implemented to perform this study. 
Project Design 
 This quasi-experimental study utilized an educational intervention for parents of 
PCMS students emphasizing cancer prevention as the purpose behind vaccinating against 
HPV with the 9-valent Gardasil vaccine.  Data collected was quantitative in nature and 
was collected using the CHC’s KidCare van vaccine tracking database.  Vaccination rates 
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were collected from the database in the six week period after education was administered 
and was then compared to vaccination rates from the same six week period during the 
prior year to determine if increased parental knowledge of cancer prevention benefits 
initiated an increase in parental/legal guardian consent for vaccination against HPV. 
Sample 
 Target Population 
 Upon approval from SEK CHC, PCMS, and Pittsburg State University, 
parent/legal guardian education was presented during parent/teacher conferences on 
October 16th, 17th, and 19th, 2018 at the PCMS campus.  The target population for this 
study consisted of parents/legal guardians of 11 to 14 year olds attending PCMS that have 
yet to consent for their child to receive HPV vaccination.  Recruitment consisted of an 
educational mailer notifying parents of the CHC’s presence and direct one-on-one 
encounters during conference times.  Inclusion criteria for this study consisted of 
parents/legal guardians who have not yet consented to HPV vaccination for their child.  
Those who have either initiated and/or completed the Gardasil 9 series were not targeted 
for the educational intervention and statistical data only reflected those that have 
consented to begin the vaccination series.  Those who receive the second Gardasil 9 
injection (to complete the series) during the six week post-education period were 
excluded from this study’s data collection. 
 Protection of Human Subjects 
 All interactions with subjects remained anonymous.  No personal information was 
obtained from parents participating in the educational intervention.  The vaccination data 
collected did not include any personal identifiers.  Data collection occurred after the 
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proper institutional review process (IRB) at Pittsburg State University and the Irene 
Ransom Bradley School of Nursing had been completed and final approval was given. 
Data was then divided by age group and gender and entered in to a spreadsheet but no 
other identifiable information was collected throughout this study.  All data collection 
was conducted with the KidCare van’s electronic records.  Records or databases utilized 
by PCMS will not be a source of data for this research.  Adherence to criteria for 
including human subjects set forth by Pittsburg State University and SEK CHC were 
upheld throughout the research process by the researcher.   
Instruments 
 To enhance the educational intervention additional resources will be utilized.  The 
local chapter of the American Cancer Society has produced two public service 
announcements (PSAs) on the importance of HPV vaccination, featuring two local 
physicians.  One or both of these videos were playing on a loop during the conference 
times.  The CHC has been granted unlimited access to both of these PSAs to use at their 
discretion to improve local HPV vaccination rates.  The collaboration of the researcher 
with the CHC allowed the PSAs to be incorporated into the study’s educational 
intervention. 
 An HPV educational mailer (Appendix B) was mailed in bulk to all parents of 
students enrolled at PCMS one week prior to parent-teacher conferences and the same 
mailer was available throughout conference times.  This mailer included a letter to 
parents informing them of the CHC and researcher’s presence during parent/teacher 
conferences and their availability to provide additional information and answer questions.  
The mailer also included the KidCare van schedule for PCMS, how the vaccine is 
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administered, and the process for follow-up to ensure the series is completed with the 
second injection.  At the end of the mailer, reliable and research based websites (i.e. 
www.cdc.gov, www.cancer.gov, www.chcsek.org) were provided as avenues for further 
education.  Additionally, the CHC KidCare van Consent to Vaccinate form was included.  
Lastly, a CDC parent information sheet completed the mailer.  The PDF was retrieved 
from the CDC’s website and provided an overview of HPV and its cancer-causing 
potential. 
 A cross-sectional questionnaire survey on resistance to vaccination (Appendix A) 
was administered to those parents/legal guardians recruited during parent-teacher 
conferences to provide insight to parental barriers against HPV vaccination.  The survey 
inquired about lack of education, lack of provider recommendation, religious beliefs, and 
age of child as potential reasons behind refusing the Gardasil vaccine.  This tool was 
implemented to enhance the validity of the study’s results and future attempts at 
educating on HPV vaccination to directly target parental reservations to vaccinate. 
Implied consent was assumed with completion and return of the survey. 
Procedure 
 Assistance and cooperation from multiple parties was necessary to design this 
study and remained essential until its completion.  Contact was made with Dawn McNay 
at the CHC to discuss project details and obtain permission to collaborate with this 
researcher’s study, to be performed in conjunction with steps the CHC was taking to 
fulfill requirements of their Innovation immunization grant.  Since no patient-specific 
information was necessary for data collection in this study, no legal/signed agreement 
was required by the CHC, other than the standard HIPPA and confidentiality forms. 
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 The study idea was then presented to the superintendent of the school district.  At 
this meeting, permission was granted to proceed with HPV education during parent-
teacher conferences as a public health initiative.  Again, because no personal parent 
and/or student information was collected, a legal agreement between the researcher and 
the school district is not a requirement.  According to the superintendent, the researcher’s 
involvement is encompassed under the existing legal agreement between the school 
district and the CHC.  HPV vaccine protocol and procedure was then discussed with the 
PCMS principal and on-campus school nurse.  The parent-teacher conference process 
was discussed with the school principal to determine the optimal location for parent 
traffic during conferences and the potential population sample size. 
 One week prior to parent-teacher conferences, the HPV educational mailer was 
mailed to all parents/legal guardians of students enrolled at PCMS by the school district’s 
head office.  The educational presentation took place on October 16th and 17th, 2018 from 
3:30pm-7:00pm and October 19th, 2018 from 8:00am-12:00pm.  As parents checked-in 
for conferences, researchers inquired about HPV vaccination for their children.  For 
parents who refused vaccination, they were asked to complete an opt-out survey.  The 
parents who had not yet authorized HPV vaccination were asked to watch the short PSA 
video available and the researcher provided them with CDC and American Cancer 
Society HPV educational handouts.  The contents of the educational mailer were 
reviewed with the parents/legal guardians and any questions were addressed.  
Parents/legal guardians were then be encouraged to either submit consent to vaccinate 
immediately or complete the opt-out survey. 
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 At the completion of the three conference sessions, synthesis and analysis of 
survey data and opt-out forms was performed.  The CHC KidCare van vaccination 
electronic records databases were accessed and HPV vaccination rates from October 25th, 
2017 thru November 30th, 2017 were collected to determine vaccination rates when no 
HPV education was provided.  The CHC databases were accessed again six weeks post-
education (after November 30th, 2018) to evaluate current HPV vaccination rates.  Data 
collected included age, race and gender of those receiving the initial injection of the 
Gardasil 9 series. 
Limitations 
 Although the study was designed to reach all parents/legal guardians of students 
enrolled in PCMS, it is limited by those parents that did not respond to the educational 
mailer and did not attend parent/teacher conferences.  Additionally, because HPV 
vaccination is not required for school attendance or to be reported to the state, the 
percentage of students already vaccinated, or vaccinated outside of the KidCare van is 
unable to be determined, skewing the actual percentage of vaccinated students.  Parental 
education level regarding HPV and the Gardasil 9 vaccine were not evaluated, therefore 
making it difficult to determine the degree of effectiveness of the educational mailer and 
one-on-one educational encounters.  Lack of an interpreter for non-english speaking 
parents was another limitation of this study. 
Evaluation Plan 
 The goal of the data collected was to determine whether or not knowledge of HPV 
vaccination as a modality for cancer prevention increases parental consent for initiation 
of the Gardasil 9 series in 11 to 14 year olds attending PCMS, when compared to rates 
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from the previous year.  In comparing vaccination rates from the same time frame from 
the previous year and six weeks post-education, a rise in rates would indicate the need for 
improved parent education on HPV vaccination and its cancer preventing capabilities. 
 The data retrieved from the KidCare van electronic records was divided by 
gender, race and age (11,12,13,&14).  The data was entered into spreadsheets, analyzed, 
and then tables created to depict the vaccination rate comparisons from the two years.  
The survey items were assigned a number (1-4), entered into a spreadsheet, analyzed, and 
formatted into a graph to illustrate the parental barriers to HPV vaccination.  The survey 
results are an important addition to the data gathered because they may indicate how 
future educational interventions could be tailored to help directly address parental 
concerns.  Depending on what the analysis shows, education interventions similar to the 
one implemented in this study could be replicated in other school districts. 
Plan for Sustainability 
If HPV education emphasizing cancer prevention proves effective in increasing HPV 
vaccination rates among 11 to 14 year olds attending PCMS, annual or bi-annual attempts 
toward parent education using the format implemented in this study would be warranted 
to use in multiple school districts throughout southeast Kansas to improve the areas 
overall vaccination coverage.  Plans to execute a universal educational intervention to be 
used throughout the counties in southeast Kansas would require a multidisciplinary 
approach in order to ensure sustainability.  Collaboration between the various community 
health clinics and surrounding school districts would be essential for the replication and 
implementation of the parent HPV education program utilized in this study. 
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Summary 
 This chapter discussed in detail the population to be studied and procedure for 
study development and data collection.  By comparing vaccination rates post-education to 
those in the prior year (with no education offered), we can assess if HPV education that 
focuses on cancer prevention plays a key role in obtaining parental consent to vaccinate, 
therefore, decreasing the long-term cancer risks associated with HPV exposure and 
infection. 
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Chapter IV 
 
 
Evaluation of Results 
 
 
Purpose 
 The purpose of this study was to compare HPV vaccination rates at Pittsburg 
Community Middle School after cancer-prevention education was provided at the 2018 
parent-teacher conferences, to the rates from the previous year, when no education was 
provided, and to determine if education emphasizing cancer-prevention increased 
parental consent to begin the Gardasil 9 series for immunization against HPV.  In 
addition, an opt-out survey was administered to willing parent/legal guardian participants 
to attempt to determine the barriers present preventing consent to vaccinate, so future 
education can be designed to directly address these concerns.  Analysis of the data 
indicates cancer-prevention education targeted at parents/legal guardians of 11 to 14 year 
olds enrolled in PCMS did increase vaccination against HPV.  Through data analysis, we 
can determine if middle schools in the remaining districts of Southeast Kansas could 
experience an increase in HPV vaccination rates among 11-14 year olds in those areas, 
therefore improving the overall vaccination status of the state of Kansas.  This chapter 
discusses the population that was studied and analysis of the data collected as it relates to 
the project’s purpose. 
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Sample 
 Once approval was gained from Pittsburg State University, SEK Community 
Health Center, and the school district’s superintendent, data collection began at the 
completion of the six week period after parent-teacher conferences.  Inclusion criteria for 
this study were adolescents (11 to 14 years old) enrolled in PCMS whose parents/legal 
guardians consented to initiate the Gardasil 9 vaccine series through the CHC’s KidCare 
Van between October 25th, 2017-November, 29th , 2017 and October 25th , 2018-
November 29th , 2018.  Those who completed the Gardasil 9 series during these time 
frames were excluded from the study’s population. 
 Data collection consisted of gathering PCMS’s total student population and then 
the number of students in each grade (6th, 7th, & 8th) was determined.  The number of 
parents/legal guardians who attended the 2018 parent/teacher conferences was also 
obtained so parental/legal guardian attendance for each grade could be decided as well.  
The student data collected was separated by gender, age, grade, and race/ethnicity.  
Project Variables 
 The independent variable for this study was the education provided to the PCMS 
parents/legal guardians.  The education, which emphasized the cancer-preventing benefits 
of HPV vaccination, included the informational mailer, which was mailed one week prior 
to the conferences, and the live one-on-one encounters with the additional educational 
tools from the CDC and American Cancer Society that took place during the 2018 PCMS 
parent-teacher conferences. 
 The dependent variables were parent/legal guardian knowledge of HPV and the 
Gardasil 9 vaccine prior to the educational interventions.  The dependent variables were 
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affected by the provided education.  In some instances, that consisted of the informational 
mailer only and, in others, a combination of the mailer and the one-on-one encounters 
with the additional educational tools.  Previous HPV and Gardasil 9 knowledge was 
unable to be determined in this study; however, the perceived barriers to vaccinate were 
indicated on the opt-out survey.  The effect on the dependent variables was shown in the 
comparison of the previous year’s vaccination rates to the rates six weeks post-education. 
Analysis of Research Questions 
 At the beginning of this project, 683 students were enrolled at PCMS: 259 6th 
graders, 213 7th graders and 211 8th graders.  The number of students that had either 
begun or completed the Gardasil 9 series were determined through the KidCare Van 
databases.  Vaccination rates as of October 1st, 2018 were determined and separated into 
each grade (Table 1). 
Table 1  
Current Vaccination Rates by Grade as of 10/01/2018 
Grade Percent Vaccinated 
6 9% 
7 45% 
8 52% 
  
 There is a large jump seen in the vaccination rates from the 6th to the 7th and 8th 
grades.  The low percentage of 6th graders vaccinated is an indicator of why increased 
education and provider recommendation is important.  As mentioned in chapter 1, 
beginning in February 2015, ACIP and CDC recommend vaccination with Gardasil 9 
beginning as early as age 9.  The 259 6th grade students at PCMS have been eligible to 
begin the Gardasil 9 series for a minimum of 2 years, yet less than 10% have reported 
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initiating HPV vaccination.  The remaining 7th and 8th grade students have had access to 
the KidCare van vaccination services 1 to 2 years longer than their 6th grade counterparts 
and show significantly higher vaccination rates.  Unfortunately, vaccination rates in all 3 
grades fall well below the CDC’s goal of 80%. 
Research Question 1.  What are the perceived barriers to HPV vaccination of adolescent 
parents/legal guardians in a rural southeast Kansas school district who opt-out of HPV 
vaccination for their child and attended parent-teacher conferences? 
The perceived barriers to HPV vaccination were identified in the opt-out survey 
administered to willing parents/legal guardians who attended parent-teacher conferences.  
Unfortunately, the participation in the opt-out survey was minimal, consisting of only 
eight respondents.  The opt-out survey consisted of a four question Likert-scale with the 
responses: Strongly Agree, Agree, Neither Agree or Disagree, Disagree, and Strongly 
Disagree (Table 2).  Analysis of the opt-out survey results included a mean and SD of the 
responses to each question (Table 4). 
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Table 2 
Responses to opt-out survey (n=8) 
 Strongly 
Agree 
Agree Neither 
Agree or 
Disagree 
Disagree Strongly 
Disagree 
I need more education 
about HPV and Gardasil 
 
25% 63% 13% 0% 0% 
My child’s doctor did not 
recommend HPV 
vaccination 
 
0% 38% 63% 0% 0% 
HPV vaccination conflicts 
with our religious beliefs 
 
13% 0% 50% 13% 25% 
My child is too young to 
learn about HPV 
38% 38% 25% 0% 0% 
 
The first question on the survey, “I need more education about HPV and Gardasil”, 63% 
of participants Agreed, 25% Strongly Agreed, and 13% Neither Agreed or Disagreed.  
None of the participants answered with Disagree or Strongly Disagree.  The mean 
response to this question was Agree.  The response to question #2, “My child’s doctor did 
not or has not recommended HPV vaccination”, was split between Agree (38%) and 
Neither Agree or Disagree (63%), and had a mean answer of Neither Agree or Disagree.  
Question #3, “HPV conflicts with our religious beliefs” had a predominately neutral 
response (50%); however, both 13% Strongly Agreed & Disagreed, resulting in a mean 
of Disagree.  None of the participants Disagreed or Strongly Disagreed with the last 
question, “My child is too young to learn about HPV”.  The mean response to this 
question was Agree. 
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Table 3 
Agreement Scale 
 
Response Standard Deviation 
Strongly Agree 
 
4.5-5.0 
Agree 
 
3.5-4.49 
Neither Agree or Disagree 
 
2.5-3.49 
Disagree 
 
1.5-2.49 
Strongly Disagree 1-1.49 
 
Table 4 
Mean & SD of opt-out survey responses (n=8) 
 Mean SD 
I need more education about HPV and 
Gardasil 
 
4.13 .64 
My child’s doctor did not or has not 
recommended HPV vaccination 
 
3.38 .52 
HPV vaccination conflicts with our 
religious beliefs 
 
2.63 1.3 
My child is too young to learn about 
HPV 
4.13 .83 
  
The SD for questions 1, 2, & 4 was less than 1, which indicates little variation among the 
replies.  The SD for question 3 was greater than 1 at 1.3, showing a much broader 
reaction to this topic.  Overall, the majority of respondents Agreed more education was 
required and the age their child was an issue in consenting to vaccination. 
Research Question 2.  Will education focusing on cancer prevention increase parental 
consent to vaccinate against HPV in 11 to 14 year olds among the parents/legal guardians 
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that received the mailer and those who received the mailer, as well as attended parent-
teacher conferences in 2018? 
Parent-teacher conference attendance was determined to efficiently answer this research 
question.  The total number of parents attending parent-teacher conferences was collected 
with the assistance of the KidCare van nurse practitioner and the PCMS school nurse 
(Table 5). 
Table 5 
2018 Parent-teacher conference attendance by grade 
Grade Parental Attendance 
6 57% 
7 45% 
8 39% 
  
Parent/legal guardian attendance was then further analyzed to verify which parents/legal 
guardians did not attend the conferences but did receive the informational mailer versus 
the group who both received the informational mailer and the live one-on-one educational 
encounters by being present at one of the conference sessions.  Through the KidCare Van 
immunization databases, the children with parents/legal guardians in these groups were 
identified.  The students’ information was then categorized by gender, age, grade, and 
race/ethnicity. 
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Table 6 
Vaccine initiation between 10/25/18-11/29/18 for those who received the informational 
mailer only 
Gender Age Grade Race/Ethnicity 
Male 13 7 Caucasian 
Male 12 7 Biracial 
Male 13 8 Caucasian 
Male 11 6 Caucasian 
Male 12 6 African/American 
Male 12 6 African/American 
Male 13 7 African/American 
 
Table 7  
Vaccine initiation between 10/25/18-11/29/18 for those who received the informational 
mailer and the one-on-one educational encounter at parent-teacher conferences 
Gender Age Grade Race/Ethnicity 
Female 11 6 Caucasian 
Female 12 6 Caucasian 
Female 13 7 Caucasian 
Female 12 7 Caucasian 
Male 13 7 Caucasian 
Female 13 8 Caucasian 
 
Tables 5 and 7 show a correlation between parent/legal guardian attendance and vaccine 
initiation.  Sixth and seventh graders were also the larger group with consent to vaccinate 
among those who did not attend any of the conference sessions.  The KidCare van 
administered the first Gardasil 9 injection to a total of 13 PCMS students in the six weeks 
post education. 
Research Question 3.  Will the SEK Community Health Center KidCare school health 
van see an increase in vaccination among 11 to 14 year olds six weeks post education in 
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children whose parents/legal guardians received the informational mailer and those that 
received the mailer and one-on-one education at parent-teacher conferences vs the 2017 
fall semester when no education was provided? 
KidCare van immunization databases were accessed to determine the number of students 
who were consented to initiate the Gardasil-9 series in the fall of 2017 between the dates 
of October 25th and November 29th (Table 8). 
Table 8 
Vaccine initiation between 10/25/17-11/29/17 when no education was provided 
Gender Age Grade Race 
Female 12 7 Caucasian 
Female 12 6 Caucasian 
Male 12 6 Hispanic 
Female 12 6 Caucasian 
Male 13 7 Caucasian 
Male 12 7 Asian/Islander 
 
There were a total of 6 students who initiated HPV vaccination in the fall of 2017, when 
no education was provided.  There was an equal rate of consent among 6th & 7th graders.  
No 8th graders received the initial injection. 
 When comparing tables 3, 4, & 5, there is an increase in the number of students 
that began the Gardasil 9 series.  During the fall of 2017, a total of 6 students (3 boys, 3 
girls) in the 6th and 7th grades only received the first Gardasil 9 shot through the KidCare 
van.  At project completion (11/29/18), 13 students (8 boys, 5 girls) from all grades began 
the HPV vaccine series with the van, doubling the total from the previous year.  This 
increase in vaccination by grade level caused a school-wide vaccination rate increase as 
well (Table 9). 
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Table 9 
Comparison of school vaccination rates by grade from before project and at project 
completion 
Grade 10/01/18 Vaccination Rate 11/29/18 Vaccination Rate 
6 9% 12% 
7 45% 48% 
8 52% 53% 
 
Summary 
 Results of data analysis and comparison revealed findings significant to the 
purpose of the study.  The research was designed to show HPV education, with an 
emphasis on cancer-prevention, increases the likelihood of parental consent to vaccinate 
with Gardasil 9 among the 11 to 14 year old age group.  Research outcomes indicate 
education focusing on the cancer-preventing benefits of vaccinating against HPV may 
have a positive effect on obtaining vaccination consent.   
 When no attempt was made for an educational intervention, only 6 in a student 
body population of 683 received the Gardasil 9 shot through the KidCare van in the fall 
of 2017.  After implementation of an educational intervention targeted at the parents/legal 
guardians of this age group, there was an increase in consent to vaccinate, with each 
grade experiencing a rise in the percent of students vaccinated by project completion. 
 The attempt was made in this study to identify parental barriers that reflect current 
vaccination concerns.  Although the opt-out survey response was minimal, evaluation of 
the collected data does help to provide insight on parental barriers to vaccinate.  Even 
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with the small response, lack of education and child’s age stood out as factors that may 
be inhibiting a more significant rise of vaccinated children in the 11 to 14 year old age 
group. 
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Chapter V 
 
 
Discussion 
 
 
The intention of this project was to evaluate the effects of an educational intervention 
focusing on the cancer prevention benefits of HPV vaccination in the 11 to 14 year old 
age group.  The number of students who initiated the Gardasil 9 series from October 25th, 
2017-November 29th, 2017 were compared to the students who initiated the series in the 
same time frame in 2018 after HPV vaccine education was implemented at the 2018 
parent-teacher conferences.  The data collected indicates HPV vaccine education, with an 
emphasis on cancer prevention, does increase parental consent to initiate the Gardasil 9 
series among 11 to 14 year olds.   
Relationship of Outcomes to Research 
 The 11 to 14 year old age group is the prime cohort to be vaccinated against HPV 
because most have yet to be exposed to the virus (Castle & Maza, 2015).  The project 
questions address parental barriers and the effects of HPV vaccine education on parental 
consent to vaccinate.  Previous research has also addressed these factors to provide 
insight on how vaccination efforts can be improved in order to reach the CDC’s 2020 
goal of an 80% nation-wide HPV vaccination rate, in both males and females. 
 The opt-out survey was utilized in this study to attempt to identify parental 
barriers toward HPV vaccination in order to customize future educational interventions to 
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directly address these concerns.  From the topics addressed in the survey, both lack of 
education about HPV and Gardasil 9 and the child’s age were the barriers most 
participants agreed were inhibiting them from providing consent to have their child 
vaccinated.  These findings do coincide with barriers identified in prior research.  In 
studies where an effort to increase HPV vaccine knowledge was made, an increase in 
consent to vaccinate was noted (Vielot et al., 2017; Brown, Gobra, & Pellman, 2017; 
VanWormer, et al., 2017; Cates et al., 2011).  Rise in vaccine initiation was as low as 2% 
in one study, but there was an increase nonetheless (Cates et al., 2011).  Previous studies 
also recognized “lack of provider recommendation” as a primary reason Gardasil 9 had 
yet to be initiated in the 11 to 14 year old age group (Brown, Gobra, & Pellman, 2017).  
However, the opt-out survey participants responded neutrally regarding this topic, which 
was inconsistent with the studies reviewed for this project.  This may be attributed to only 
8 surveys being returned for data collection and analysis. 
 Provider intervention, which served as the basis for this study, has also proven 
effective in increasing HPV vaccination rates in this study’s targeted age group 
(Henninger et al., 2017; McLean et al., 2017).  The informational mailer and live one-on-
one education encounters were designed to enhance trust, rapport, and communication 
between PCMS parents/legal guardians, the SEK CHC, KidCare van nurse practitioner, 
and the immunization services they provide.  These were identified as key components by 
a study conducted at the Kaiser Permanente Center in Portland, Oregon, when developing 
an educational intervention to increase parental consent to vaccinate against HPV 
(Henninger et al., 2017).  Effectiveness of education designed with these factors in mind 
was reflected in both groups of parents/legal guardians (those that received the 
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informational mailer only and those who received the mailer and attended one of the 
parent-teacher conference sessions) in this study.  Seven students initiated the Gardasil 9 
vaccine in the group that received the informational mailer only and six students inititated 
the Gardasil 9 vaccine whose parents/legal guardians received the mailer and attended 
one of the parent-teacher conference sessions.  When the data collected from these two 
groups was compared to the same six week time period from the previous year, where no 
education was provided, a significant increase in the students beginning the Gardasil 9 
series was noted.  Between October 25th and November 29th, 2017, six PCMS students 
were allowed by their parents/legal guardians to initiate HPV vaccination through the 
CHC KidCare van.  Thirteen students began the series with the KidCare van during this 
same time frame in 2018 after the educational intervention was implemented.  
Considering the number of students vaccinated essentially doubled, the educational 
intervention designed based on prior research findings coincides with the results seen in 
other studies where similar designs were utilized.  However, other studies where a 
provider-mediated educational intervention was implemented outside of the clinical 
setting were not found for review in this project.  Therefore, the basis for comparison 
between the school setting and clinical setting may not be unilateral. 
Observations 
 Noteworthy observations of this study include the amount of education required 
to make an impact on HPV vaccination.  With implementation of the HPV educational 
intervention, in the form of the informational mailer and live one-on-one encounters, a 
notable increase in the number of students who received the initial Gardasil 9 injection 
was seen in comparison to the previous year.  The overall results shown in this study are 
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reassuring for improving vaccination rates in 11 to 14 year olds.  The one-on-one 
educational encounters were a reiteration of the information included in the mailer with 
the addition of the PSA announcements and printed fact sheets from the reputable 
websites mentioned in the mailer.  However, the results showed more parents/legal 
guardians gave consent to vaccinate in the group that received the informational mailer 
only. There was not a significant difference between the two groups, with the mailer only 
group being larger by one student but it is curious the group that received additional 
education by attending parent-teacher conferences had the same rate of consent.   
Therefore, indicating that more education may not be directly proportional to a higher 
rate of vaccination. 
 An additional noteworthy finding is the gender of the students that were 
ultimately vaccinated.  Only parents of male students consented to HPV vaccination 
based on the education provided in the informational mailer alone.  In the parent group 
that received the mailer and attended parent-teacher conferences, all but one of the 
students consent was provided for were female.  Although the study results revealed HPV 
vaccine education emphasizing cancer-prevention benefits had a positive effect on the 
vaccination rates in all grades at PCMS, the data did not indicate the amount of education 
appropriate to instigate the desired response. 
Evaluation of Theoretical Framework 
 The theoretical framework applied in this study was the Vaccine Perceptions, 
Accountability, and Adherence model.  In order to achieve vaccine adherence, vaccine 
acceptance among the involved parties must occur (Katz et al., 2010).  This study was 
designed with that very premise in mind.  The educational interventions implemented in 
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this study focused on getting parents/legal guardians to view and accept the HPV vaccine 
as cancer prevention, not STI prevention.  For this mind set to be accomplished, barriers 
to acceptance had to be addressed as well.  The framework selected addresses multiple 
potential barriers experienced by parents/legal guardians and the adolescent themselves.  
Although adolescent behavior leading to vaccine inhibiting factors was not included in 
this study, the barriers on the part of the caregiver were taken in to account.  The primary 
structural and societal factor proposed in this model and included in the study was 
vaccine availability and cost.  The informational mailer and live one-on-one education 
made parents/legal guardians aware both injections in the Gardasil 9 series were offered 
at the school and at no cost to them.  The opt-out survey included a few of the topics 
related to the model’s caregiver barriers.  Health beliefs and healthcare utilization were 
imbedded into the questions regarding HPV and Gardasil 9 knowledge, provider 
recommendation, and religious beliefs affecting healthcare decisions.  However, the 
barriers were merely identified in this study and not addressed with education designed to 
directly answer or clarify caregiver concerns.   
 In some instances, parent/legal guardian acceptance of HPV vaccination occurred 
with the additional education provided in the informational mailer and live one-on-one 
encounters only.  This led to authorization of consent to vaccinate through the KidCare 
van, and eventual adherence due to the child being entered into the KidCare van’s 
database and flagged to complete the Gardasil 9 series.  The Vaccine Perceptions, 
Accountability, and Adherence framework was reflected in these cases. 
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Evaluation of Logic Model 
In Chapter 1, a logic model was provided to show the short, intermediate, and 
long term outcomes of implementing an educational intervention emphasizing the cancer-
preventing benefits of HPV vaccination in 11 to 14 year old adolescents enrolled in 
PCMS.  The logic model shows the components necessary to develop a successful 
intervention and the parties required for collaboration.  Initial input required to develop 
and implement HPV education to the parents of PCMS students occurred between the 
researcher and the SEK CHC.  The Immunization Innovation Grant awarded to the CHC 
set the parameters for the timing and planning of the study.  Additional input and 
permission was required in the early development stages from the USD 250 
superintendent, PCMS administrative staff and school nurse, and CHC KidCare van.  The 
informational mailer and live one-on-one educational sessions at the 2018 parent-teacher 
conferences were the educational interventions described in the outputs of the logic 
model.  The pre and post-education PCMS vaccination rates are also included in the 
outputs of the logic model. 
 An increase in 11-14 year old PCMS students vaccinated against HPV was 
depicted in the short-term outcomes of the logic model and supported by the study’s 
results.  Change in HPV vaccine perception and increase parent HPV education were 
addressed throughout the study but were not measured, and therefore were not supporting 
this aspect of the logic model.  The intermediate and long-term outcomes were a 
projection of future effects that extend beyond the time frame in which this study was 
completed, which was not proven with the results of this study.  However, achievement 
of these outcomes is promising based upon this data analysis. 
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Limitations 
 Even though the results supported the purpose of the research, this study is not 
without bias and limiting factors.  One area of bias can be seen in the lack of a Spanish 
interpreter’s presence at the live one-on-one encounters at parent-teacher conferences.  A 
Spanish copy of the informational mailer was included in every mailer sent but the 
absence of an advocate at the conference sessions may have hindered the willingness of 
Spanish parents to provide consent to vaccinate.  The data gives basis to this speculation 
because there were no Hispanic students vaccinated from either parent group after the 
2018 conference sessions. 
 Evaluation of parent/legal guardians prior and current HPV knowledge was not 
measured in this project.  The informational mailer and live one-on-one educational 
encounters were designed with the mindset that parent/legal guardians had none to 
minimal knowledge of HPV vaccination as it relates to cancer prevention.  A tangible 
method to accurately determine parent/legal guardian HPV and Gardasil 9 knowledge 
would have indicated the type and level of education necessary to instigate providing 
consent to vaccinate.  In this study’s results, it is difficult to know if the parents/legal 
guardians who received the mailer only consented to vaccination because they possessed 
a higher knowledge of HPV and/or Gardasil 9 than the group that required the 
informational mailer and live one-on-one educational encounters to authorize consent. 
 Time also played a factor in data collection and analysis.  Because this study was 
conducted in collaboration with the CHC’s Immunization Innovation Grant, educational 
interventions had to be implemented within the specific time frame outlined in the grant.  
As a result of the time constraints, tools and instruments developed were unable to be 
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revised and edited prior to the conference dates.  The time allotted for data collection 
could also be considered a limiting factor.  Six weeks post-education is an adequate 
amount of time to determine effectiveness of the educational interventions implemented, 
but a longer time frame for research may have yielded greater results. 
 The most significant limiting factor in this study is the opt-out survey 
administered at the conference sessions.  As mentioned previously, time constraints did 
not allow for editing and revisions.  The first question on the survey, “I need more 
education about HPV and Gardasil 9”, would have provided more statistically relevant 
responses if it had been broken into two separate questions, one asking about HPV 
education and another inquiring about Gardasil 9 education.  The survey also lacked 
questions regarding Gardasil 9 side effects.  Parental concerns of adverse side effects 
could negatively affect vaccine uptake if not thoroughly addressed.  Additionally, the 
minimal survey response limits the study as well.  The eight surveys collected and 
analyzed aid in providing insight about parental barriers to HPV vaccination, but such a 
small response neither proves nor disproves any one factor as a predominant barrier to 
vaccinate. 
Implications for Future Research 
 Less than 39% of age eligible Kansas residents have been vaccinated against HPV 
(Kansas HPV vaccination rates, 2019).  In southeast Kansas, only 7-13% of 11-18 year 
olds have completed the Gardasil 9 series (Kansas HPV vaccination rates, 2019).  With 
the knowledge that HPV is responsible for a multitude of cancers affecting both men and 
women, developing an initiative to increase vaccination rates is crucial.  Targeting the 
age group likely not to have been exposed to the virus is also beneficial if there is going 
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to be a significant impact on reducing HPV-related cancers.  These low statistics provide 
the necessary evidence to support and develop projects to identify parental barriers to 
HPV vaccination and provide education on the cancer-preventing benefits of the Gardasil 
9 series, specifically in the 11-14 year old age group.   
This author’s project has provided a solid foundation for further research into the realm 
of improving HPV vaccination rates in adolescents.  It would be beneficial for future 
research to include a method to determine the level and source of a caregiver’s HPV and 
Gardasil 9 knowledge prior to any education provided.  These results could help 
researchers better understand the type and amount of education necessary to increase 
parent/legal guardian acceptance of HPV vaccination as a cancer prevention modality. 
The gender discrepancy noted in this study’s results warrants further research to 
determine if the adolescent’s gender plays a role in the information and education 
necessary to authorize vaccination.  The findings of this research suggest parents/legal 
guardians of female children may require more education on HPV and the Gardasil 9 
vaccine prior to authorizing consent for immunization than those with male children.  
This would provide valuable information in the development of future educational 
interventions. 
Identifying specific parental barriers to HPV vaccination is another crucial point that 
requires more research.  Although the opt-out survey utilized in this study was limited, 
the previously discussed revisions could make it a valuable tool for future research.  
Additionally, an effort to increase survey participation would make any data collected 
more sound and reliable when developing educational interventions.  By understanding 
the amount of education needed and which concerns to directly address, great strides 
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could be made in creating acceptance of and adherence to HPV vaccination of 11 to 14 
year old adolescents. 
Implications for Practice, Policy, and Education 
 In rural communities, parents/legal guardians are not fully aware of HPV and its 
cancer-causing capabilities (Thomas, 2016).  Routine vaccination against HPV in the 
clinical practice setting would reduce the incidence of future diagnoses.  Many initiatives 
have been implemented in the southeast Kansas region to trigger an increase in 
vaccination.  The CHC’s Immunization Innovation grant is an example of one of these 
initiatives.  This author worked in collaboration with CHC to fulfill the requirements of 
the grant.  The research project developed and implemented by this author was included 
in the action plan of the grant and the study’s results were included in the grant’s final 
report.  Additionally, the data collected in this study was reported to the Quality 
Assurance Committee at CHC during their monthly meeting in February 2019 (Appendix 
C).  At this meeting, replication of this project in the other school districts served by CHC 
was proposed as a future initiative to increase HPV vaccination rates throughout the 
southeast Kansas region. 
 The CHC’s partnership was invaluable to this project and led to the Merck 
(manufacturer of Gardasil 9) representative for southeast Kansas to reach out to this 
author for further inquiry regarding the project’s methodology.  Significant interest on 
behalf of the Merck representative awarded this author an invitation to present this study 
and its findings at the March 2019 meeting of the Kansas Immunization Coalition.  
Meeting attendance included representatives from Merck, American Cancer Society, 
SEK CHC, Crawford County Health Department, Ascension Via Christi Oncology, and 
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Kansas University Cancer Education Outreach.  The data collected in this study was 
presented and the informational mailer and opt-out survey were provided to those in 
attendance as well.  The CHC representative expressed interest on behalf of the CHC’s 
school health coordinator to replicate this study in the other southeast Kansas school 
districts serviced by CHC.  Additionally, the Merck representative articulated interest in 
implementing use of the informational mailer in Johnson County Kansas school districts.  
Potential use of this study’s methodology and educational tools outside of southeast 
Kansas speaks volumes toward the validity of this research. 
Conclusion 
 In conclusion, the aim of this scholarly project was to increase HPV vaccine 
uptake of the PCMS student body through parent-targeted HPV education that 
emphasizes cancer prevention.  Comparison of vaccination rates from October 25th-
November 29th in 2017 and 2018 showed an increase in the number of students who 
began the Gardasil 9 series after education was provided. The outcome of the study 
enhanced the awareness of healthcare providers about the importance of parental HPV 
education in improving vaccine uptake.  Even though the study’s results are promising on 
the effectiveness of cancer prevention HPV education on vaccine initiation, 
recommendations for further research were addressed.  The results of the project 
determined additional research is warranted to determine the HPV education level 
necessary for consent to vaccinate to occur.  In order to achieve an HPV vaccination rate 
of at least 80%, providers must continue to educate patients and their parents/legal 
guardians on the cancer-preventing benefits of Gardasil 9.  High vaccination rates are 
associated with a decrease in HPV diagnosis (Katz et al., 2010).  If vaccination uptake 
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does not increase among 11 to 14 year olds, healthcare providers will continue to spend 
time and resources diagnosing and treating HPV-related cancers.  The need for continued 
attempts at caregiver acceptance of HPV vaccination as cancer prevention is as crucial as 
ever.  The poet Maya Angelou stated, “Do the best you can until you know better.  Then 
when you know better, do better.”  This quote effectively describes the development, 
implementation, and future possibilities of this scholarly work.  The education created 
and carried out in this project placed a great deal of emphasis on overcoming the known 
barriers against HPV vaccination and communicating the cancer-preventing benefits of 
vaccinating with Gardasil 9.  The data collected in this study presents opportunities to 
learn more about caregiver concerns, that lead to improved educational interventions and 
a better effort on behalf of healthcare providers to create acceptance of HPV vaccination 
as cancer prevention. 
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